💹 NASDAQ: GNPX - Tackling Two Killer Diseases with Game Changing Gene Therapies

It's All about the MOMENTUM and this one looks like it's just getting started! [View online]( [UNSUBSCRIBE]( NEW ALERT: ** NASDAQ: GNPX ** Alright!! Before I get to the full report on our New Alert NASDAQ: GNPX let me start just showing you this AMAZING News the company just announced Yesterday and TODAY! Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers Provides Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial AUSTIN, Texas, Aug. 16, 2022 /PRNewswire/ -- [Genprex, Inc.]( ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex U.S. Patent No: 11,278,592 B2. The patent covers methods of using REQORSATM Immunogene Therapy in conjunction with immune checkpoint inhibitors, through 2038. FULL Release here: Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial AUSTIN, Texas, Aug. 15, 2022 /PRNewswire/ -- [Genprex, Inc.]( ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the trial. In 2020, Genprex received U.S. Food and Drug Administration's (FDA) Fast Track Designation for treatment of the Acclaim-1 patient population. FULL Release here: Alright so if those News announcements don't get you EXCITED then how about the Technicals!! On Investing .com it's showing the Hourly Technical Analysis as "STRONG BUY" with 12 Moving Average Indicators as a BUY and 0 as Sell! For the Technical Indicators it shows 7 as a BUY, and 0 as Sell... See the image below for yourself: Cancer… Diabetes… this Emerging NASDAQ Company is Tackling Two Killer Diseases with Game Changing Gene Therapies. Greetings All, The biotech space is one of the most exciting to keep an eye on… this is because the medicines and therapies being worked on by such companies have the potential to help millions of people. Take for example the notable growth story of Moderna, who played an instrumental role in the development of the first vaccine during the pandemic. The company’s share price flew from under $20 to nearly $500 in a couple of years! The key is to finding companies that have yet to become household names who have tremendous revenue potential with strong drug developments in various stages of development. That brings us to a small-cap biotech company trading on the NASDAQ that is working on several very exciting things! Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company is focused on developing life-changing therapies for patients with cancer and diabetes. The company believes that it has the FIRST systemic gene therapy delivery platform used for cancer in humans! They also have a gene therapy that replace daily burden of blood glucose monitoring and insulin replacement therapy for diabetic patients, including finger pricks and insulin injections. The therapy could possibly be a cure for diabetes! With therapies that can help the world and FDA fast track designation already happening, NASDAQ small-cap company Genprex Inc. (NASDAQ: GNPX) could be one of the biggest discoveries hiding in the biotech arena. NASDAQ: GNPX     [FULL Report on NASDAQ: GNPX](   Copyright 2022 © TopStockTips is owned and operated by Momentum Marketing LLC and owner of CareBear Marketing Group LLC. [Disclaimer and PrivacyÂ]( more Information please contact editor@topstocktips.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. This communication includes advertising material and PAID ADVERTISEMENTS provided to our subscribers. Company Address: 26 Downing Street, Newark NJ 07105. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.  CareBear Marketing Group, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly.  Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TST” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in GNPX. We have been compensated up to Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Legends Media LLC Group for a 3 Day Marketing Program regarding GNPX with a start date of 8/15/2022 to 8/17/2022. TST’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. , Rua Frei Tome de Jesus N18 1Dto, 1700-215, Lisboa, Portugal You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](